GC MS said that it has obtained an export approval for GENEDIA W COVID-19 Ag, a point of care testing (POCT) antigen diagnosis kit, from the Ministry of Food and Drug Safety.
GC MS has received export approval for GENEDIA W COVID-19 Ag, a Covid-19 diagnostic kit, from the Ministry of Drug and Safety. (GC MS)
The device is an antigen-diagnosing kit that detects Covid-19 infection on-site within 10 minutes by using a nasopharyngeal and sputum sample to visually check Covid-19 patients in their early stages without additional equipment.
“The demand for such diagnostic kits is increasing in developing countries where medical infrastructure is weak and there are few expensive gene amplification (PCR) equipment,” the company said. “
With the approval, the company has five Covid-19 diagnostic kits, including two antibody diagnostic kits and two molecular diagnostic kits, approved for export.
The company expects that it will be able to respond to different demands by strengthening its lineup efficiently.
“The newest product is likely to be in demand as a field diagnosis method required before and after administering a Covid-19 vaccine,” GC MS CEO Ahn Eun-eok said. “In the future, we plan to build an integrated diagnostic platform related to Covid-19 by adding fluorescent immunity products.”
Exhibitor Data Sheet